Metabolic Syndrome Prevalence Study

Metabolic Syndrome Clinical Trial

Official title:

Turkey Metabolic Syndrome Prevalence Study - METSAR II

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02379702
• Other study ID #: METSAR-II
• Status: Completed
• Phase: N/A
• First received: October 17, 2014
• Last updated: March 2, 2015
• Start date: June 2014
• Est. completion date: November 2014

Study information

• Verified date: March 2015
• Source: Abdi Ibrahim Ilac San. ve Tic A.S.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Following the first study conducted to investigate the prevalence of metabolic syndrome and its components in Turkey, it was aimed to demonstrate the change in general health condition of available patients after the period of time lapsed. This study will provide important information on the social and economic dimensions of metabolic syndrome and will contribute to development of preventive programs.

Description:

In the first METSAR-I study conducted in 2003, metabolic syndrome screening was made by two different team. Participants were visited at their addresses and informed about the research study and gave written consent. They were invited on an empty stomach for hospital visit on the day after. Pre-trained nurses completed the forms of patients during that second visit. After 11 years, a questionnaire by telephone survey will be applied to patients who participated in the METSAR-II study. The main goal is to determine the changes of metabolic syndrome population during that period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1659
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Volunteers who participated in the METSAR-I study in 2003

• Patients who accepted to participate will be included the second follow up phase.

Exclusion Criteria:

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Other:
• Metabolic Syndrome
This study will provide important information on the social and economic dimensions of metabolic syndrome

Locations

Country	Name	City	State
Turkey	Ankara University	Ankara
Turkey	Gazi University	Ankara
Turkey	Yuksek Ihtisas Hospital	Ankara
Turkey	Istanbul Cerrahpasa University	Istanbul
Turkey	Istanbul Medeniyet University	Istanbul
Turkey	Prof. Dr. Omer Kozan	Izmir

Sponsors (1)

Lead Sponsor	Collaborator
Abdi Ibrahim Ilac San. ve Tic A.S.

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	comorbidities and changes in general health		10 year	No